Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study
KE Kip, EK McCreary, K Collins, TE Minnier… - Annals of Internal …, 2023 - acpjournals.org
Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of …
Introduction Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), including administration of booster doses, continues to be the most effective method …
CoV-2), including administration of booster doses, continues to be the most effective method …
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
Understanding the antibody response to SARS-CoV-2, the virus responsible for COVID-19,
is crucial to comprehending disease progression and the significance of vaccine and …
is crucial to comprehending disease progression and the significance of vaccine and …
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2
Background Due to COVID-19, pandemic preparedness emerges as a key imperative,
necessitating new approaches to accelerate development of reagents against infectious …
necessitating new approaches to accelerate development of reagents against infectious …
[HTML][HTML] Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
MF Pavan, M Bok, RB San Juan, JP Malito… - bioRxiv, 2023 - ncbi.nlm.nih.gov
In this work, we developed llama-derived nanobodies (Nbs) directed to the receptor binding
domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies …
domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies …
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate …
G Poulakou, PJ Royer, N Evgeniev, G Evanno… - Frontiers in …, 2024 - frontiersin.org
Introduction XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
A novel monospecific tetravalent IgG1-(scFv)2 version shown enhanced neutralizing and Fc-mediated effector functions against SARS-CoV-2
Z Gao, J Jiao, Y Zhou, J Qi, S Zhu, J Xu, L Nie, H Wang - 3 Biotech, 2023 - Springer
Neutralizing monoclonal antibodies (nMABs) have been proved to be effective therapeutics
in treating coronavirus disease (COVID-19). To enhance the potency of nMAB 553–15, we …
in treating coronavirus disease (COVID-19). To enhance the potency of nMAB 553–15, we …
[HTML][HTML] Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization
T Ciaglia, V Vestuto, V Di Sarno, S Musella… - European Journal of …, 2024 - Elsevier
In this paper we present the design, synthesis, and biological evaluation of a new series of
peptidomimetics acting as potent anti-SARS-CoV-2 agents. Starting from our previously …
peptidomimetics acting as potent anti-SARS-CoV-2 agents. Starting from our previously …
Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of
effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the …
effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the …
[HTML][HTML] The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
MG Bigotti, K Klein, ES Gan, M Anastasina… - Antiviral Research, 2024 - Elsevier
The COVID-19 pandemic has shown the need to develop effective therapeutics in
preparedness for further epidemics of virus infections that pose a significant threat to human …
preparedness for further epidemics of virus infections that pose a significant threat to human …